Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease
Don D Sin, Bruce E Miller, Annelyse Duvoix, S F Paul Man, Xuekui Zhang, Edwin K Silverman, John E Connett, Nicholas A Anthonisen, Robert A Wise, Donald Tashkin, Bartolome R Celli, Lisa D Edwards, Nicholas Locantore, William Macnee, Ruth Tal-Singer, David A Lomas, ECLIPSE Investigators, Yavor Ivanov, Kosta Kostov, Jean Bourbeau, Mark Fitzgerald, Paul Hernandez, Kieran Killian, Robert Levy, Francois Maltais, Denis O'Donnell, Jan Krepelka, Jørgen Vestbo, Emiel Wouters, Dean Quinn, Per Bakke, Mitja Kosnik, Alvar Agusti, Jaume Sauleda, Yuri Feschenko, Vladamir Gavrisyuk, Lyudmila Yashina, Nadezhda Monogarova, Peter Calverley, David Lomas, William MacNee, David Singh, Jadwiga Wedzicha, Antonio Anzueto, Sidney Braman, Richard Casaburi, Bart Celli, Glenn Giessel, Mark Gotfried, Gary Greenwald, Nicola Hanania, Don Mahler, Barry Make, Stephen Rennard, Carolyn Rochester, Paul Scanlon, Dan Schuller, Frank Sciurba, Amir Sharafkhaneh, Thomas Siler, Edwin Silverman, Adam Wanner, Robert Wise, Richard ZuWallack, Harvey Coxson, Lisa Edwards, Katharine Knobil, David Lomas, William MacNee, Edwin Silverman, Ruth Tal-Singer, Jørgen Vestbo, Julie Yates, Alvar Agusti, Peter Calverley, Bartolome Celli, Courtney Crim, Gerry Hagan, William MacNee, Bruce Miller, Stephen Rennard, Ruth Tal-Singer, Emiel Wouters, Julie Yates, Don D Sin, Bruce E Miller, Annelyse Duvoix, S F Paul Man, Xuekui Zhang, Edwin K Silverman, John E Connett, Nicholas A Anthonisen, Robert A Wise, Donald Tashkin, Bartolome R Celli, Lisa D Edwards, Nicholas Locantore, William Macnee, Ruth Tal-Singer, David A Lomas, ECLIPSE Investigators, Yavor Ivanov, Kosta Kostov, Jean Bourbeau, Mark Fitzgerald, Paul Hernandez, Kieran Killian, Robert Levy, Francois Maltais, Denis O'Donnell, Jan Krepelka, Jørgen Vestbo, Emiel Wouters, Dean Quinn, Per Bakke, Mitja Kosnik, Alvar Agusti, Jaume Sauleda, Yuri Feschenko, Vladamir Gavrisyuk, Lyudmila Yashina, Nadezhda Monogarova, Peter Calverley, David Lomas, William MacNee, David Singh, Jadwiga Wedzicha, Antonio Anzueto, Sidney Braman, Richard Casaburi, Bart Celli, Glenn Giessel, Mark Gotfried, Gary Greenwald, Nicola Hanania, Don Mahler, Barry Make, Stephen Rennard, Carolyn Rochester, Paul Scanlon, Dan Schuller, Frank Sciurba, Amir Sharafkhaneh, Thomas Siler, Edwin Silverman, Adam Wanner, Robert Wise, Richard ZuWallack, Harvey Coxson, Lisa Edwards, Katharine Knobil, David Lomas, William MacNee, Edwin Silverman, Ruth Tal-Singer, Jørgen Vestbo, Julie Yates, Alvar Agusti, Peter Calverley, Bartolome Celli, Courtney Crim, Gerry Hagan, William MacNee, Bruce Miller, Stephen Rennard, Ruth Tal-Singer, Emiel Wouters, Julie Yates
Abstract
Rationale: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum.
Objectives: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality.
Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study.
Measurements and main results: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort.
Conclusions: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.
Trial registration: ClinicalTrials.gov NCT00292552.
Figures
Source: PubMed